Review



c diff quik chek complete immunochromatographic test kit  (Abbott Laboratories)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Abbott Laboratories c diff quik chek complete immunochromatographic test kit
    C Diff Quik Chek Complete Immunochromatographic Test Kit, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c%2E+diff+quik+chek+complete+test/c+chek+complete+diff+quik/pmc12719486-74-17-25
    Average 86 stars, based on 1 article reviews
    c diff quik chek complete immunochromatographic test kit - by Bioz Stars, 2026-11
    86/100 stars

    Images

    Related Articles

    Enzyme-linked Immunosorbent Assay:

    Article Title: A multicenter evaluation of a sample to answer real-time PCR assay for toxigenic C. difficile in symptomatic subjects.
    Article Snippet: Abbreviations: PPA, positive predictive agreement; N ment; CDI,C. difficile infection; CCNA, cell culture neutraliz noassay; NAAT, nucleic acid amplification test.. ⁎ Corresponding author.. Tel.

    Article Title: Multi-omic Analysis of the Interaction between Clostridioides difficile Infection and Pediatric Inflammatory Bowel Disease.
    Article Snippet: C.difficile testingwasperformedby theCHOPMicrobiologyLaboratoryusinga two-stepprocess.First, sampleswere tested forglutamate dehydrogenase antigen and toxin A/B antigen using the C. DIFF QUIK CHEKCOMPLETE test (Alere North America, Inc.).

    Article Title: Impact of the Introduction of a Two-Step Laboratory Diagnostic Algorithm in the Incidence and Earlier Diagnosis of Clostridioides difficile Infection
    Article Snippet: From 2009 to 2012, the diagnostic technique was a combined EIA, the C. DIFF QUIK CHEK COMPLETE ® test (Abbott Laboratories, Chicago, IL, USA), which detects CD-specific GDH and CD toxin A/B in the fecal specimen.

    Article Title: Hypervirulent clade 2, ribotype 019/sequence type 67 Clostridioides difficile strain from Japan
    Article Snippet: Bacterial identification was performed using the C. DIFF QUIK CHEK COMPLETE test (Abbott Diagnostics Medical, Tokyo, Japan) and confirmed by 16S rRNA gene sequencing [ ] for quality assurance of the following data.

    Article Title: Clinical significance of toxin EIA positivity in patients with suspected Clostridioides difficile infection: systematic review and meta-analysis
    Article Snippet: Sopena, 2022 ( ) , Spain , Retrospective , 9* , 443; evaluation of the two-step algorithm , NAAT+/EIA− vs NAAT+/EIA+ , NAAT: GenomEra CD (Abacus Diagnostica) EIA: C. DIFF QUIK CHEK COMPLETE test (Abbott) , Mortality, recurrence, fulminant CDI.

    Article Title: Prognosis of Clostridium difficile infection in adult oncohaematological patients: experience from a large prospective observational study.
    Article Snippet: The aim of the study is to evaluate demographics, epidemiology, clinical characteristics, treatment and outcomes of Clostridium difficile infection (CDI) in patients with and without concurrent cancer.. This is a prospective cohort study of consecutive primary CDI episodes in adults (January 2006–December 2016).. CDI was diagnosed on the presence of diarrhoea and positive stool testing for toxigenic C. difficile.

    Diff-Quik:

    Article Title: A multicenter evaluation of a sample to answer real-time PCR assay for toxigenic C. difficile in symptomatic subjects.
    Article Snippet: Abbreviations: PPA, positive predictive agreement; N ment; CDI,C. difficile infection; CCNA, cell culture neutraliz noassay; NAAT, nucleic acid amplification test.. ⁎ Corresponding author.. Tel.

    Article Title: Multi-omic Analysis of the Interaction between Clostridioides difficile Infection and Pediatric Inflammatory Bowel Disease.
    Article Snippet: C.difficile testingwasperformedby theCHOPMicrobiologyLaboratoryusinga two-stepprocess.First, sampleswere tested forglutamate dehydrogenase antigen and toxin A/B antigen using the C. DIFF QUIK CHEKCOMPLETE test (Alere North America, Inc.).

    Article Title: Impact of the Introduction of a Two-Step Laboratory Diagnostic Algorithm in the Incidence and Earlier Diagnosis of Clostridioides difficile Infection
    Article Snippet: From 2009 to 2012, the diagnostic technique was a combined EIA, the C. DIFF QUIK CHEK COMPLETE ® test (Abbott Laboratories, Chicago, IL, USA), which detects CD-specific GDH and CD toxin A/B in the fecal specimen.

    Article Title: Hypervirulent clade 2, ribotype 019/sequence type 67 Clostridioides difficile strain from Japan
    Article Snippet: Bacterial identification was performed using the C. DIFF QUIK CHEK COMPLETE test (Abbott Diagnostics Medical, Tokyo, Japan) and confirmed by 16S rRNA gene sequencing [ ] for quality assurance of the following data.

    Article Title: Clinical significance of toxin EIA positivity in patients with suspected Clostridioides difficile infection: systematic review and meta-analysis
    Article Snippet: Sopena, 2022 ( ) , Spain , Retrospective , 9* , 443; evaluation of the two-step algorithm , NAAT+/EIA− vs NAAT+/EIA+ , NAAT: GenomEra CD (Abacus Diagnostica) EIA: C. DIFF QUIK CHEK COMPLETE test (Abbott) , Mortality, recurrence, fulminant CDI.

    Article Title: Prognosis of Clostridium difficile infection in adult oncohaematological patients: experience from a large prospective observational study.
    Article Snippet: The aim of the study is to evaluate demographics, epidemiology, clinical characteristics, treatment and outcomes of Clostridium difficile infection (CDI) in patients with and without concurrent cancer.. This is a prospective cohort study of consecutive primary CDI episodes in adults (January 2006–December 2016).. CDI was diagnosed on the presence of diarrhoea and positive stool testing for toxigenic C. difficile.

    Multiplex Assay:

    Article Title: A multicenter evaluation of a sample to answer real-time PCR assay for toxigenic C. difficile in symptomatic subjects.
    Article Snippet: Abbreviations: PPA, positive predictive agreement; N ment; CDI,C. difficile infection; CCNA, cell culture neutraliz noassay; NAAT, nucleic acid amplification test.. ⁎ Corresponding author.. Tel.

    Article Title: Multi-omic Analysis of the Interaction between Clostridioides difficile Infection and Pediatric Inflammatory Bowel Disease.
    Article Snippet: C.difficile testingwasperformedby theCHOPMicrobiologyLaboratoryusinga two-stepprocess.First, sampleswere tested forglutamate dehydrogenase antigen and toxin A/B antigen using the C. DIFF QUIK CHEKCOMPLETE test (Alere North America, Inc.).

    Article Title: Impact of the Introduction of a Two-Step Laboratory Diagnostic Algorithm in the Incidence and Earlier Diagnosis of Clostridioides difficile Infection
    Article Snippet: From 2009 to 2012, the diagnostic technique was a combined EIA, the C. DIFF QUIK CHEK COMPLETE ® test (Abbott Laboratories, Chicago, IL, USA), which detects CD-specific GDH and CD toxin A/B in the fecal specimen.

    Article Title: Hypervirulent clade 2, ribotype 019/sequence type 67 Clostridioides difficile strain from Japan
    Article Snippet: Bacterial identification was performed using the C. DIFF QUIK CHEK COMPLETE test (Abbott Diagnostics Medical, Tokyo, Japan) and confirmed by 16S rRNA gene sequencing [ ] for quality assurance of the following data.

    Article Title: Clinical significance of toxin EIA positivity in patients with suspected Clostridioides difficile infection: systematic review and meta-analysis
    Article Snippet: Sopena, 2022 ( ) , Spain , Retrospective , 9* , 443; evaluation of the two-step algorithm , NAAT+/EIA− vs NAAT+/EIA+ , NAAT: GenomEra CD (Abacus Diagnostica) EIA: C. DIFF QUIK CHEK COMPLETE test (Abbott) , Mortality, recurrence, fulminant CDI.

    Article Title: Prognosis of Clostridium difficile infection in adult oncohaematological patients: experience from a large prospective observational study.
    Article Snippet: The aim of the study is to evaluate demographics, epidemiology, clinical characteristics, treatment and outcomes of Clostridium difficile infection (CDI) in patients with and without concurrent cancer.. This is a prospective cohort study of consecutive primary CDI episodes in adults (January 2006–December 2016).. CDI was diagnosed on the presence of diarrhoea and positive stool testing for toxigenic C. difficile.

    Comparison:

    Article Title: A multicenter evaluation of a sample to answer real-time PCR assay for toxigenic C. difficile in symptomatic subjects.
    Article Snippet: Abbreviations: PPA, positive predictive agreement; N ment; CDI,C. difficile infection; CCNA, cell culture neutraliz noassay; NAAT, nucleic acid amplification test.. ⁎ Corresponding author.. Tel.

    Article Title: Multi-omic Analysis of the Interaction between Clostridioides difficile Infection and Pediatric Inflammatory Bowel Disease.
    Article Snippet: C.difficile testingwasperformedby theCHOPMicrobiologyLaboratoryusinga two-stepprocess.First, sampleswere tested forglutamate dehydrogenase antigen and toxin A/B antigen using the C. DIFF QUIK CHEKCOMPLETE test (Alere North America, Inc.).

    Article Title: Impact of the Introduction of a Two-Step Laboratory Diagnostic Algorithm in the Incidence and Earlier Diagnosis of Clostridioides difficile Infection
    Article Snippet: From 2009 to 2012, the diagnostic technique was a combined EIA, the C. DIFF QUIK CHEK COMPLETE ® test (Abbott Laboratories, Chicago, IL, USA), which detects CD-specific GDH and CD toxin A/B in the fecal specimen.

    Article Title: Hypervirulent clade 2, ribotype 019/sequence type 67 Clostridioides difficile strain from Japan
    Article Snippet: Bacterial identification was performed using the C. DIFF QUIK CHEK COMPLETE test (Abbott Diagnostics Medical, Tokyo, Japan) and confirmed by 16S rRNA gene sequencing [ ] for quality assurance of the following data.

    Article Title: Clinical significance of toxin EIA positivity in patients with suspected Clostridioides difficile infection: systematic review and meta-analysis
    Article Snippet: Sopena, 2022 ( ) , Spain , Retrospective , 9* , 443; evaluation of the two-step algorithm , NAAT+/EIA− vs NAAT+/EIA+ , NAAT: GenomEra CD (Abacus Diagnostica) EIA: C. DIFF QUIK CHEK COMPLETE test (Abbott) , Mortality, recurrence, fulminant CDI.

    Article Title: Prognosis of Clostridium difficile infection in adult oncohaematological patients: experience from a large prospective observational study.
    Article Snippet: The aim of the study is to evaluate demographics, epidemiology, clinical characteristics, treatment and outcomes of Clostridium difficile infection (CDI) in patients with and without concurrent cancer.. This is a prospective cohort study of consecutive primary CDI episodes in adults (January 2006–December 2016).. CDI was diagnosed on the presence of diarrhoea and positive stool testing for toxigenic C. difficile.

    Real-time Polymerase Chain Reaction:

    Article Title: A multicenter evaluation of a sample to answer real-time PCR assay for toxigenic C. difficile in symptomatic subjects.
    Article Snippet: Abbreviations: PPA, positive predictive agreement; N ment; CDI,C. difficile infection; CCNA, cell culture neutraliz noassay; NAAT, nucleic acid amplification test.. ⁎ Corresponding author.. Tel.

    Article Title: Multi-omic Analysis of the Interaction between Clostridioides difficile Infection and Pediatric Inflammatory Bowel Disease.
    Article Snippet: C.difficile testingwasperformedby theCHOPMicrobiologyLaboratoryusinga two-stepprocess.First, sampleswere tested forglutamate dehydrogenase antigen and toxin A/B antigen using the C. DIFF QUIK CHEKCOMPLETE test (Alere North America, Inc.).

    Article Title: Impact of the Introduction of a Two-Step Laboratory Diagnostic Algorithm in the Incidence and Earlier Diagnosis of Clostridioides difficile Infection
    Article Snippet: From 2009 to 2012, the diagnostic technique was a combined EIA, the C. DIFF QUIK CHEK COMPLETE ® test (Abbott Laboratories, Chicago, IL, USA), which detects CD-specific GDH and CD toxin A/B in the fecal specimen.

    Article Title: Hypervirulent clade 2, ribotype 019/sequence type 67 Clostridioides difficile strain from Japan
    Article Snippet: Bacterial identification was performed using the C. DIFF QUIK CHEK COMPLETE test (Abbott Diagnostics Medical, Tokyo, Japan) and confirmed by 16S rRNA gene sequencing [ ] for quality assurance of the following data.

    Article Title: Clinical significance of toxin EIA positivity in patients with suspected Clostridioides difficile infection: systematic review and meta-analysis
    Article Snippet: Sopena, 2022 ( ) , Spain , Retrospective , 9* , 443; evaluation of the two-step algorithm , NAAT+/EIA− vs NAAT+/EIA+ , NAAT: GenomEra CD (Abacus Diagnostica) EIA: C. DIFF QUIK CHEK COMPLETE test (Abbott) , Mortality, recurrence, fulminant CDI.

    Article Title: Prognosis of Clostridium difficile infection in adult oncohaematological patients: experience from a large prospective observational study.
    Article Snippet: The aim of the study is to evaluate demographics, epidemiology, clinical characteristics, treatment and outcomes of Clostridium difficile infection (CDI) in patients with and without concurrent cancer.. This is a prospective cohort study of consecutive primary CDI episodes in adults (January 2006–December 2016).. CDI was diagnosed on the presence of diarrhoea and positive stool testing for toxigenic C. difficile.

    Diagnostic Assay:

    Article Title: A multicenter evaluation of a sample to answer real-time PCR assay for toxigenic C. difficile in symptomatic subjects.
    Article Snippet: Abbreviations: PPA, positive predictive agreement; N ment; CDI,C. difficile infection; CCNA, cell culture neutraliz noassay; NAAT, nucleic acid amplification test.. ⁎ Corresponding author.. Tel.

    Article Title: Multi-omic Analysis of the Interaction between Clostridioides difficile Infection and Pediatric Inflammatory Bowel Disease.
    Article Snippet: C.difficile testingwasperformedby theCHOPMicrobiologyLaboratoryusinga two-stepprocess.First, sampleswere tested forglutamate dehydrogenase antigen and toxin A/B antigen using the C. DIFF QUIK CHEKCOMPLETE test (Alere North America, Inc.).

    Article Title: Impact of the Introduction of a Two-Step Laboratory Diagnostic Algorithm in the Incidence and Earlier Diagnosis of Clostridioides difficile Infection
    Article Snippet: From 2009 to 2012, the diagnostic technique was a combined EIA, the C. DIFF QUIK CHEK COMPLETE ® test (Abbott Laboratories, Chicago, IL, USA), which detects CD-specific GDH and CD toxin A/B in the fecal specimen.

    Article Title: Hypervirulent clade 2, ribotype 019/sequence type 67 Clostridioides difficile strain from Japan
    Article Snippet: Bacterial identification was performed using the C. DIFF QUIK CHEK COMPLETE test (Abbott Diagnostics Medical, Tokyo, Japan) and confirmed by 16S rRNA gene sequencing [ ] for quality assurance of the following data.

    Article Title: Clinical significance of toxin EIA positivity in patients with suspected Clostridioides difficile infection: systematic review and meta-analysis
    Article Snippet: Sopena, 2022 ( ) , Spain , Retrospective , 9* , 443; evaluation of the two-step algorithm , NAAT+/EIA− vs NAAT+/EIA+ , NAAT: GenomEra CD (Abacus Diagnostica) EIA: C. DIFF QUIK CHEK COMPLETE test (Abbott) , Mortality, recurrence, fulminant CDI.

    Article Title: Prognosis of Clostridium difficile infection in adult oncohaematological patients: experience from a large prospective observational study.
    Article Snippet: The aim of the study is to evaluate demographics, epidemiology, clinical characteristics, treatment and outcomes of Clostridium difficile infection (CDI) in patients with and without concurrent cancer.. This is a prospective cohort study of consecutive primary CDI episodes in adults (January 2006–December 2016).. CDI was diagnosed on the presence of diarrhoea and positive stool testing for toxigenic C. difficile.

    Enzyme Immunoassay:

    Article Title: A multicenter evaluation of a sample to answer real-time PCR assay for toxigenic C. difficile in symptomatic subjects.
    Article Snippet: Abbreviations: PPA, positive predictive agreement; N ment; CDI,C. difficile infection; CCNA, cell culture neutraliz noassay; NAAT, nucleic acid amplification test.. ⁎ Corresponding author.. Tel.

    Article Title: Multi-omic Analysis of the Interaction between Clostridioides difficile Infection and Pediatric Inflammatory Bowel Disease.
    Article Snippet: C.difficile testingwasperformedby theCHOPMicrobiologyLaboratoryusinga two-stepprocess.First, sampleswere tested forglutamate dehydrogenase antigen and toxin A/B antigen using the C. DIFF QUIK CHEKCOMPLETE test (Alere North America, Inc.).

    Article Title: Impact of the Introduction of a Two-Step Laboratory Diagnostic Algorithm in the Incidence and Earlier Diagnosis of Clostridioides difficile Infection
    Article Snippet: From 2009 to 2012, the diagnostic technique was a combined EIA, the C. DIFF QUIK CHEK COMPLETE ® test (Abbott Laboratories, Chicago, IL, USA), which detects CD-specific GDH and CD toxin A/B in the fecal specimen.

    Article Title: Hypervirulent clade 2, ribotype 019/sequence type 67 Clostridioides difficile strain from Japan
    Article Snippet: Bacterial identification was performed using the C. DIFF QUIK CHEK COMPLETE test (Abbott Diagnostics Medical, Tokyo, Japan) and confirmed by 16S rRNA gene sequencing [ ] for quality assurance of the following data.

    Article Title: Clinical significance of toxin EIA positivity in patients with suspected Clostridioides difficile infection: systematic review and meta-analysis
    Article Snippet: Sopena, 2022 ( ) , Spain , Retrospective , 9* , 443; evaluation of the two-step algorithm , NAAT+/EIA− vs NAAT+/EIA+ , NAAT: GenomEra CD (Abacus Diagnostica) EIA: C. DIFF QUIK CHEK COMPLETE test (Abbott) , Mortality, recurrence, fulminant CDI.

    Article Title: Prognosis of Clostridium difficile infection in adult oncohaematological patients: experience from a large prospective observational study.
    Article Snippet: The aim of the study is to evaluate demographics, epidemiology, clinical characteristics, treatment and outcomes of Clostridium difficile infection (CDI) in patients with and without concurrent cancer.. This is a prospective cohort study of consecutive primary CDI episodes in adults (January 2006–December 2016).. CDI was diagnosed on the presence of diarrhoea and positive stool testing for toxigenic C. difficile.

    Sequencing:

    Article Title: A multicenter evaluation of a sample to answer real-time PCR assay for toxigenic C. difficile in symptomatic subjects.
    Article Snippet: Abbreviations: PPA, positive predictive agreement; N ment; CDI,C. difficile infection; CCNA, cell culture neutraliz noassay; NAAT, nucleic acid amplification test.. ⁎ Corresponding author.. Tel.

    Article Title: Multi-omic Analysis of the Interaction between Clostridioides difficile Infection and Pediatric Inflammatory Bowel Disease.
    Article Snippet: C.difficile testingwasperformedby theCHOPMicrobiologyLaboratoryusinga two-stepprocess.First, sampleswere tested forglutamate dehydrogenase antigen and toxin A/B antigen using the C. DIFF QUIK CHEKCOMPLETE test (Alere North America, Inc.).

    Article Title: Impact of the Introduction of a Two-Step Laboratory Diagnostic Algorithm in the Incidence and Earlier Diagnosis of Clostridioides difficile Infection
    Article Snippet: From 2009 to 2012, the diagnostic technique was a combined EIA, the C. DIFF QUIK CHEK COMPLETE ® test (Abbott Laboratories, Chicago, IL, USA), which detects CD-specific GDH and CD toxin A/B in the fecal specimen.

    Article Title: Hypervirulent clade 2, ribotype 019/sequence type 67 Clostridioides difficile strain from Japan
    Article Snippet: Bacterial identification was performed using the C. DIFF QUIK CHEK COMPLETE test (Abbott Diagnostics Medical, Tokyo, Japan) and confirmed by 16S rRNA gene sequencing [ ] for quality assurance of the following data.

    Article Title: Clinical significance of toxin EIA positivity in patients with suspected Clostridioides difficile infection: systematic review and meta-analysis
    Article Snippet: Sopena, 2022 ( ) , Spain , Retrospective , 9* , 443; evaluation of the two-step algorithm , NAAT+/EIA− vs NAAT+/EIA+ , NAAT: GenomEra CD (Abacus Diagnostica) EIA: C. DIFF QUIK CHEK COMPLETE test (Abbott) , Mortality, recurrence, fulminant CDI.

    Article Title: Prognosis of Clostridium difficile infection in adult oncohaematological patients: experience from a large prospective observational study.
    Article Snippet: The aim of the study is to evaluate demographics, epidemiology, clinical characteristics, treatment and outcomes of Clostridium difficile infection (CDI) in patients with and without concurrent cancer.. This is a prospective cohort study of consecutive primary CDI episodes in adults (January 2006–December 2016).. CDI was diagnosed on the presence of diarrhoea and positive stool testing for toxigenic C. difficile.



    Similar Products

    c diff quik chek complete immunochromatographic test kit  (Abbott Laboratories)
    86
    Abbott Laboratories c diff quik chek complete immunochromatographic test kit
    C Diff Quik Chek Complete Immunochromatographic Test Kit, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c%2E+diff+quik+chek+complete+test/c+chek+complete+diff+quik/pmc12719486-74-17-25
    Average 86 stars, based on 1 article reviews
    c diff quik chek complete immunochromatographic test kit - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier
    c diff quik chek complete lateral flow test  (Abbott Laboratories)
    86
    Abbott Laboratories c diff quik chek complete lateral flow test
    C Diff Quik Chek Complete Lateral Flow Test, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c%2E+diff+quik+chek+complete+test/c+chek+complete+diff+quik/pmc12566496-111-28-36
    Average 86 stars, based on 1 article reviews
    c diff quik chek complete lateral flow test - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier
    rapid immunoenzyme test for glutamate dehydrogenase (gdh) and toxin assay c. diff quik chek complete  (TechLab Inc)
    90
    TechLab Inc rapid immunoenzyme test for glutamate dehydrogenase (gdh) and toxin assay c. diff quik chek complete
    Rapid Immunoenzyme Test For Glutamate Dehydrogenase (Gdh) And Toxin Assay C. Diff Quik Chek Complete, supplied by TechLab Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c%2E+diff+quik+chek+complete+test/c++diff+chek+60/pm39914651-46-50-57
    Average 90 stars, based on 1 article reviews
    rapid immunoenzyme test for glutamate dehydrogenase (gdh) and toxin assay c. diff quik chek complete - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    c. diff quik chek complete test  (Abbott Laboratories)
    90
    Abbott Laboratories c. diff quik chek complete test
    Characteristics of the studies included in the meta-analysis
    C. Diff Quik Chek Complete Test, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c%2E+diff+quik+chek+complete+test/c++diff+quik+chek+complete/pmc11784090-9-27-34
    Average 90 stars, based on 1 article reviews
    c. diff quik chek complete test - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    rapid immunoenzyme test for glutamate dehydrogenase (gdh) and toxin assays techlab c. diff quik chek complete  (TechLab Inc)
    90
    TechLab Inc rapid immunoenzyme test for glutamate dehydrogenase (gdh) and toxin assays techlab c. diff quik chek complete
    Characteristics of the studies included in the meta-analysis
    Rapid Immunoenzyme Test For Glutamate Dehydrogenase (Gdh) And Toxin Assays Techlab C. Diff Quik Chek Complete, supplied by TechLab Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c%2E+diff+quik+chek+complete+test/c++diff+chek+60/pm39734001-49-15-18
    Average 90 stars, based on 1 article reviews
    rapid immunoenzyme test for glutamate dehydrogenase (gdh) and toxin assays techlab c. diff quik chek complete - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    toxin antigen test for c. difficile tech lab c. diff quik chek complete  (TechLab Inc)
    90
    TechLab Inc toxin antigen test for c. difficile tech lab c. diff quik chek complete
    Characteristics of the studies included in the meta-analysis
    Toxin Antigen Test For C. Difficile Tech Lab C. Diff Quik Chek Complete, supplied by TechLab Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c%2E+diff+quik+chek+complete+test/c++diff+chek+60/pm39716657-36-6-15
    Average 90 stars, based on 1 article reviews
    toxin antigen test for c. difficile tech lab c. diff quik chek complete - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    rapid membrane enzyme immunoassay c. diff quik chek complete test  (TechLab Inc)
    90
    TechLab Inc rapid membrane enzyme immunoassay c. diff quik chek complete test
    Characteristics of the studies included in the meta-analysis
    Rapid Membrane Enzyme Immunoassay C. Diff Quik Chek Complete Test, supplied by TechLab Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c%2E+diff+quik+chek+complete+test/c++diff+quick+check+complete+enzyme+immunoassay/pmc11350807-233-16-27
    Average 90 stars, based on 1 article reviews
    rapid membrane enzyme immunoassay c. diff quik chek complete test - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    rapid immunoenzyme test for glutamate dehydrogenase and toxin techlab c. diff quik chek complete kit  (TechLab Inc)
    90
    TechLab Inc rapid immunoenzyme test for glutamate dehydrogenase and toxin techlab c. diff quik chek complete kit
    Characteristics of the studies included in the meta-analysis
    Rapid Immunoenzyme Test For Glutamate Dehydrogenase And Toxin Techlab C. Diff Quik Chek Complete Kit, supplied by TechLab Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c%2E+diff+quik+chek+complete+test/c++diff+chek+60/10__2147_slash_idr__s459708-47-16-17
    Average 90 stars, based on 1 article reviews
    rapid immunoenzyme test for glutamate dehydrogenase and toxin techlab c. diff quik chek complete kit - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    c. diff quik chek complete® dual-antigen eia test  (TechLab Inc)
    90
    TechLab Inc c. diff quik chek complete® dual-antigen eia test
    Characteristics of the studies included in the meta-analysis
    C. Diff Quik Chek Complete® Dual Antigen Eia Test, supplied by TechLab Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c%2E+diff+quik+chek+complete+test/c++diff+quik+chek+complete/pmc10663888-99-7-16
    Average 90 stars, based on 1 article reviews
    c. diff quik chek complete® dual-antigen eia test - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Characteristics of the studies included in the meta-analysis

    Journal: Journal of Clinical Microbiology

    Article Title: Clinical significance of toxin EIA positivity in patients with suspected Clostridioides difficile infection: systematic review and meta-analysis

    doi: 10.1128/jcm.00977-24

    Figure Lengend Snippet: Characteristics of the studies included in the meta-analysis

    Article Snippet: Sopena, 2022 ( ) , Spain , Retrospective , 9* , 443; evaluation of the two-step algorithm , NAAT+/EIA− vs NAAT+/EIA+ , NAAT: GenomEra CD (Abacus Diagnostica) EIA: C. DIFF QUIK CHEK COMPLETE test (Abbott) , Mortality, recurrence, fulminant CDI.

    Techniques: Enzyme-linked Immunosorbent Assay, Multiplex Assay, Comparison, Diff-Quik, Real-time Polymerase Chain Reaction, Diagnostic Assay, Enzyme Immunoassay